Paul Clancy Biography and Net Worth

Paul J. Clancy is an Independent Director of Incyte Corporation. Mr. Clancy has more than 30 years of experience in financial management and strategic business planning, and has served as the Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, since July 2017. Prior to joining Alexion, Mr. Clancy served as Executive Vice President, Finance and Chief Financial Officer of Biogen Inc. (formerly known as Biogen Idec Inc.), a biotechnology company, from August 2007 until June 2017. He also served as Senior Vice President of Finance of Biogen, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation to form Biogen, Mr. Clancy was the Vice President of Portfolio Management of Biogen. He joined Biogen in 2001 as Vice President of U.S. Marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a food and beverage company, serving in a variety of financial and general management positions, including Vice President and General Manager of their Great West Business Unit.

What is Paul J. Clancy's net worth?: The estimated net worth of Paul J. Clancy is at least $17.03 million as of July 10th, 2018. Mr. Clancy owns 93,309 shares of Alexion Pharmaceuticals stock worth more than $17,028,893 as of May 7th. This net worth approximation does not reflect any other investments that Mr. Clancy may own. Learn More about Paul J. Clancy's net worth.
How do I contact Paul J. Clancy?: The corporate mailing address for Mr. Clancy and other Alexion Pharmaceuticals executives is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Alexion Pharmaceuticals can also be reached via phone at 475-230-2596 and via email at [email protected]. Learn More on Paul J. Clancy's contact information.
Has Paul J. Clancy been buying or selling shares of Alexion Pharmaceuticals?: Paul J. Clancy has not been actively trading shares of Alexion Pharmaceuticals over the course of the past ninety days. Most recently, Paul J. Clancy sold 5,241 shares of the business's stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $131.11, for a transaction totalling $687,147.51. Following the completion of the sale, the chief financial officer now directly owns 93,309 shares of the company's stock, valued at $12,233,742.99. Learn More on Paul J. Clancy's trading history.
Who are Alexion Pharmaceuticals' active insiders?: Alexion Pharmaceuticals' insider roster includes Daniel Bazarko (CAO), Tanisha Carino (CAO), Paul Clancy (CFO), Indrani Franchini (EVP), Ludwig Hantson (CEO), John Orloff (EVP), Vikas Sinha (CFO), and Heidi Wagner (SVP). Learn More on Alexion Pharmaceuticals' active insiders.

Paul J. Clancy Insider Trading History at Alexion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/10/2018	Sell	5,241	$131.11	$687,147.51	93,309
2/8/2018	Sell	6,079	$116.31	$707,048.49	95,093

Paul J. Clancy Buying and Selling Activity at Alexion Pharmaceuticals

Alexion Pharmaceuticals Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $182.50

$182.50

50 Day Range

MA: $182.82

$179.45

$186.61

2 Week Range

Now: $182.50

$99.91

$187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25

Do NOT read if you believe in “woke” politics

From Stansberry Research | Ad

I have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.

Everything you need to know is posted on our website here.